NCT06650709 - NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

November 1, 2028

Conditions

Ovarian Cancer Stage IV

Interventions

DRUG

Olaparib

Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.

DRUG

Bevacizumab

Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).

DRUG

Durvalumab

Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.